MACROGENICS INC — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
MacroGenics sold its GMP drug substance manufacturing operations to Bora Pharmaceuticals for $122.5M base price (received $119.6M net cash in July 2026), reducing workforce to ~140 employees and transitioning to fully outsourced model. Pro forma cash position reached $327M (including $60M Sagard royalty monetization, $24.5M Sanofi milestone, $10M Gilead option exercise), with guidance for runway through 2028. Pipeline advancing: MGC026 (B7-H3 ADC) advancing to Stage 2, MGC030 IND cleared, lorigerlimab Phase 2 ongoing, MGC028 dose escalation underway.
Why this rating
Manufacturing sale is 165% of market cap, dramatically strengthens balance sheet (327M cash vs. 73.9M market value). Major strategic pivot reduces costs, extends runway materially. Positive but execution risk on pipeline catalysts remains.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.